Founded by R&D leaders and world-class kinase experts, Confluence is an innovator in the discovery and development of breakthrough medicines for the treatment of cancer and autoimmune/inflammatory diseases. CLS is a drug discovery and development company focusing on signal transduction targets and rational drug design to discover and develop mechanistically novel drugs for use in human and health care. Specifically, CLS focuses on the design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, metastasis and survival, or in modulation of chronic inflammation. CLS utilizes a detailed understanding of the kinase enzymes and its proprietary KINect Discovery Platform to design proprietary inhibitors that are selective and have good drug-like properties. In addition, because of demand for the team’s expertise, the company has established a CRO, Confluence Discovery Technologies, Inc., which provides research support for clients from large pharma to academic scientists. CDT has delivered >$7M in revenue since its inception.